MET and non-small cell lung carcinoma: Germline and somatic mutations in MET’s kinase domain leading to constitutive activation are seen in renal papillary carcinoma, childhood hepatocellular carcinoma and colorectal cancer [10–12], whilst intronic mutations leading to an exon 14 deleted splice variant are seen in non-small cell lung cancer (NSCLC) [6].